Ofev® media backgrounder
1. What is Ofev® (nintedanib*)?
2. How does Ofev® (nintedanib*) work?
1. What is Ofev® (nintedanib*)?
Ofev® (nintedanib*) is a small molecule tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF).1 Nintedanib* is currently approved in the US, the European Union, Japan and other territories for the treatment of IPF. Nintedanib*, one capsule twice daily, consistently slows disease progression with approximately 50% reduction in FVC decline across a broad range of IPF patient types. **2,3,4,5
2. How does Ofev® (nintedanib*) work?
Nintedanib* targets growth factor receptors, which have been shown to be involved in the mechanisms by which pulmonary fibrosis occurs. Most importantly nintedanib* inhibits plateletderived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR).1,6,7 It is believed that nintedanib* reduces disease progression in IPF and slows the decline in lung function by blocking the signalling pathways that are involved in fibrotic processes.1,6,8
Referências
1 Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.
2 Richeldi, L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071- 82.
3 Cottin V, Taniguchi H, Richeldi L, et al. Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS® trials. Abstract presented at the 18th International Colloquium on Lung and Airway Fibrosis; Mont Tremblant, Canada, September 20-24, 2014. Available at: http://iclaf.com/conference/index.php/2014/ICLAF/paper/view/151. Accessed June 11, 2015.
4 Kolb M, Richeldi L, Kimura T, Stowasser S, Hallmann C, du Bois RM. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials. Poster presented at the 110th American Thoracic Society Conference; Denver, Colorado, May 15–20, 2015.
5 Raghu G, Wells A, Nicholson AG, et al. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in IPF. Poster presented at the 110th American Thoracic Society Conference; Denver, Colorado, May 15–20, 2015.
6 Selman M, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-51.
7 Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-4782.
8 Wollin L, et al. Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. J Pharmacol Exp Ther. 2014;349:209–220
Footnotes
*Nintedanib is approved under the brand name OFEV® in the US, EU, Japan and other territories for use in patients with IPF. Nintedanib is under regulatory review by health authorities in other countries
**INPULSIS® recruited a broad range of patient types – similar to those seen in clinical practice including patients with early disease (FVC > 90% predicted), no honeycombing on HRCT and/or concomitant emphysema